跳到正文
openFDA 已分级药品召回执法报告·· 26 天前精选AI 评分73

FDA 执法报告 D-0083-2027 将 Par Health USA 的 Argatroban 注射液颗粒物召回定为 Class I

FDA drug enforcement D-0083-2027: Par Health USA, LLC — Particulate matter: particulate matter identified as cellulose, polystyrene, polyethylene teraphalate, stainless steel, or stopper material in the product solution.

AI 导读

FDA 执法报告 D-0083-2027 将 Par Health USA 的 Argatroban 注射液 250 mg/2.5mL 因颗粒物的召回定为 Class I,涉及批次 84193(效期 10/2026)与 92880(效期 08/2027),共 1944 瓶。

推荐理由

记录列出该注射剂因颗粒物召回的等级、批号与全美分销范围,可作为同类颗粒污染调查的对照样本。

正文 · 原文

FDA drug recall enforcement report — D-0083-2027

Report issued: 2026-10-28. This is the enforcement report date, not the recall initiation date.

Scope: one classified drug product recall record; event_id may group multiple products. Unclassified records without recall numbers are outside this stream. This record is not a press release or a new enforcement finding.

The openFDA dataset is updated weekly. Report status is not a live recall status and must not be used to track the recall lifecycle. Other dates below retain their named meanings.

Complete official product record (including openFDA harmonized identifiers):

{

"address_1": "870 Parkdale Rd",

"address_2": "",

"center_classification_date": "20261026",

"city": "Rochester",

"classification": "Class I",

"code_info": "Lot #: 84193, Exp Date: 10/2026; 92880, Exp Date: 08/2027.",

"country": "United States",

"distribution_pattern": "Nationwide within the United States",

"event_id": "100072",

"initial_firm_notification": "Press Release",

"more_code_info": "",

"openfda": {

"application_number": [

"ANDA091665"

],

"brand_name": [

"ARGATROBAN"

],

"generic_name": [

"ARGATROBAN"

],

"is_original_packager": [

true

],

"manufacturer_name": [

"Par Health USA, LLC"

],

"nui": [

"N0000175980",

"N0000175518",

"N0000009963"

],

"package_ndc": [

"42023-182-89"

],

"pharm_class_epc": [

"Anti-coagulant [EPC]",

"Direct Thrombin Inhibitor [EPC]"

],

"pharm_class_moa": [

"Thrombin Inhibitors [MoA]"

],

"product_ndc": [

"42023-182"

],

"product_type": [

"HUMAN PRESCRIPTION DRUG"

],

"route": [

"INTRAVENOUS"

],

"rxcui": [

"308351"

],

"spl_id": [

"493ddc78-4566-486f-8cdd-7d6868ddf153"

],

"spl_set_id": [

"1a67a87d-59cb-414c-a11e-ab8f0a9bb778"

],

"substance_name": [

"ARGATROBAN"

],

"unii": [

"IY90U61Z3S"

]

},

"postal_code": "48307-1740",

"product_description": "Argatroban Injection, USP, 250 mg/2.5mL (100 mg/mL), 2.5 mL x 1 Single Dose Vial, Rx only, Manufactured for: Endo USA, Malvern,PA 19355/ Argatroban Injection, 250 mg/2.5mL (100 mg/mL), 2.5 mL x 1 Single Dose Vial, Rx only, Distributed by: Par Pharmaceutical, Cranbury, NJ 08512, NDC 42023-182-89.",

"product_quantity": "1944 vials",

"product_type": "Drugs",

"reason_for_recall": "Particulate matter: particulate matter identified as cellulose, polystyrene, polyethylene teraphalate, stainless steel, or stopper material in the product solution.",

"recall_initiation_date": "20261013",

"recall_number": "D-0083-2027",

"recalling_firm": "Par Health USA, LLC",

"report_date": "20261028",

"state": "MI",

"status": "Ongoing",

"voluntary_mandated": "Voluntary: Firm initiated"

}

来源:openFDA 已分级药品召回执法报告 · api.fda.gov